Caribou Biosciences

👥 101-250💰 $125.0m Post-IPO Equity on 2023-07-13BiotechnologyTherapeuticsOncologyHealth Care
Website LinkedIn Email Phone # Facebook Twitter

Caribou Biosciences is a medical technology company that specializes in cell and genome engineering using the CRISPR-Cas9 technology platform. The company focuses on developing therapeutics for agricultural and industrial biotechnology, as well as basic and applied biological research.